The role of CgA is unsettled, but chaperone functions in the cellular packaging of hormones and a role as precursor for biologically active peptides have been suggested (4 -7 ) . In addition, CgA seems to be a useful marker for most neuroendocrine tumors (8 -18 ) . Even silent neuroendocrine tumors without secretion of known hormones release CgA (19 ) .
A major problem for the diagnostic use of CgA measurements is that CgA in a tissue-and tumor-specific manner is processed into a multitude of different fragments. To define the use of CgA as a marker for neuroendocrine tumors and to study the expression and processing of CgA in neuroendocrine tissue, we have now developed a library of sequence-specific RIAs for human CgA.
The aim of the present study was to describe the development and accuracy of the RIA library and to illustrate its potential. Therefore, we have measured CgA processing products in gastrointestinal tissues and neuroendocrine tumors as well as in plasma from healthy human subjects and from patients with carcinoid tumors or pituitary adenomas.
Materials and Methods nomenclature
phase HPLC, amino acid analysis, and mass spectrometry analysis.
other reagents
Na 125 I (specific activity 14.5 Ci/mg, corresponding to 2.1 Ci/mol) was purchased from Amersham International. Trypsin (specific activity, 274 U/mg protein; treated with l-tosylamido-2-phenyl ethyl chloromethyl ketone) was from Worthington Diagnostic Systems Inc. Synthetic hCgA(250 -301) amide was from Peninsula Laboratories Europe LTD.
antibodies Two alternative coupling reagents were used for producing five different human CgA antigens (Fig. 1) .
Coupling reagent I, maleimidobenzoic acid N-hydroxysuccinimide ester, was used in separate reactions to conjugate 8 mg each of CgA(1-9)-Tyr-Cys, CgA(116 -124)-Tyr-Cys, CgA(340 -348)-Tyr-Cys, and Cys-Tyr-CgA(432-439) at the Cys residues to bovine serum albumin (20 mg) . The coupled products were dissolved in 30 mL of distilled water. The antigen solution (2 mL) was mixed with 2.5 mL of a 9 g/L NaCl solution and then emulsified with an equal volume of complete Freund's adjuvant (the State Serum Institute, Denmark) and used for the first immunization. For the following booster injections, 1 mL of the antigen solution was mixed with 4 mL of a 9 g/L NaCl solution and with equal volumes of incomplete Freund's adjuvant. Four immunization series of each eight randomly bred Danish white rabbits were performed. Rabbits 94184 -94191 received injections of CgA(1-9)-Tyr-Cys; rabbits 95045-95052 received injections of CgA(116 -124)-Tyr-Cys; rabbits 95053-95060 received injections of CgA(340 -348)-Tyr-Cys; and rabbits 95037-95044 received injections of Cys-Tyr-CgA(432-439). Each rabbit received subcutaneous injections at two sites in the lower back with 1 mL of mixture at 8-week intervals. Blood (20 mL) was bled from an ear vein 10 days after immunization, and the serum was stored at Ϫ20°C for evaluation.
Coupling reagent II, bis-diazotized tolidine, was used to C-terminally conjugate 6 mg of CgA(210 -222)-Tyr to bovine serum albumin. The coupled product was then dissolved in 4.2 mL of 0.1 mol/L NH 4 HCO 3 , pH 8.0. The antigen solution (1.4 mL) was emulsified with an equal volume of complete Freund's adjuvant and used for the first immunization. For the following five booster injections, 0.7 mL of the antigen solution was mixed with 0.7 mL of 0.1 mol/L NH 4 HCO 3 , pH 8.0, and with equal volumes of incomplete Freund's adjuvant. Eight randomly bred Danish white rabbits (rabbits 1610 -1613, 1626, 1628, 1629, and 1631) recieved subcutaneous injections at three sites in the lower back with 0.3 mL of mixture per rabbit at 8-week intervals. Blood (20 mL) was bled from an ear vein every second week, and the serum was stored at Ϫ20°C for evaluation.
cga(4301 amide) assay
Immunoreactive pancreastatin [CgA(273-301) amide] was measured by RIA using antiserum 871w-1, specific for the amidated COOH terminus of pancreastatin, as detailed elsewhere (21 ) . The antiserum reacted fully with the synthetic peptides hCgA(273-301) amide and hCgA(250 -301) amide. Selected dibasic cleavage sites as well as the cleavage and amidation site (Gly-Lys) from which pancreastatin is released are indicated. The amino acid sequences used for immunizations are also shown.
preparation of tracers
The tyrosine-extended fragments of human CgACgA(1-9)-Tyr (4.4 nmol), CgA(116 -124)-Tyr (4.2 nmol), CgA(210 -222)-Tyr (2.7 nmol), CgA(340 -348)-Tyr (4.0 nmol), and Tyr-CgA(432-439) (4.5 nmol)-were monoiodinated using the chloramine-T method, as described previously (22 ) , and purified on reversed-phase HPLC (Aquapore C-8 column, RP-300, 220 ϫ 4.6 mm, 7 m bead size). The following linear gradients were used: 10 -30% ethanol (HPLC grade; Merck) for CgA(1-9)-Tyr and TyrCgA(432-439); 0 -20% ethanol for CgA(116 -124)-Tyr and CgA(340 -348)-Tyr (Fig. 2A) ; or 10 -30% acetonitrile (HPLC grade; Rathburn) for CgA(210 -222)-Tyr, all in 1.0 mL/L trifluoroacetic acid (TFA; HPLC grade; Pierce) in water. Fractions (1 mL) were collected at a flow rate of 1.0 mL/min. To evaluate the chromatographic separation of labeled and nonlabeled peptides, 1 mL of the monoiodinated peak fraction was mixed with 10 pmol of the relevant synthetic tyrosine-extended chromogranin A fragment and reapplied to the HPLC column as described. Both the radioactivity of the labeled peptides and the immunoreactivity were measured (Fig. 2B ). Using the assumption that the CgA assays measured iodinated and unlabeled fragments with identical affinity, we estimated the specific radioactivity of the tracers by self-displacement (23 ) .
extraction of tissues
Surgical specimens of healthy human neuroendocrine tissue (gastric antral mucosa, ileal mucosa, and pancreas; n ϭ 6) and neuroendocrine tumors (foregut and midgut carcinoid, and pheochromocytoma; n ϭ 6) were obtained at the Departments of Surgical Gastroenterology and Urology, Rigshospitalet, University of Copenhagen. The use of human tissue was approved by the local ethics committee, and informed consent was obtained from the patients (KF01-352/96 and KF01-290/97). Immediately after removal, the tissues were frozen in liquid nitrogen. The frozen tissue was weighed frozen within 2 h (wet weight) and subsequently stored at Ϫ80°C. Biopsies of the tissues were immersed in paraformaldehyde. Only pancreatic and gastrointestinal tissue shown to be histologically healthy as well as only nonnecrotic tumors with diagnoses verified by pathologists were included for additional studies. The tissue samples were extracted within 1 year. While frozen, the tissue was cut into pieces of a few milligrams and immersed in boiling distilled water (10 mL/g tissue) for 20 min, homogenized, and centrifuged at 10 000g for 30 min. The supernatant was subsequently stored at Ϫ20°C until analysis (boiling water extract). The pellet was reextracted by addition of 0.5 mol/L acetic acid, pH 1.5 (10 mL/g tissue), homogenized, left for 20 min at room temperature, and centrifuged as above; the supernatant was then stored at Ϫ20°C until analysis (acetic acid extract). The extracts were diluted in 20 mmol/L sodium barbital buffer, pH 8.4, containing 0.6 mmol/L merthiolate and 1.1 g/L bovine serum albumin. The extracts were analyzed in dilutions with the six CgA RIAs. The CgA peptide concentrations given below are the sums of the immunoreactivities measured in boiling water and acetic acid extracts. The extractions described above were chosen after evaluation of six different extraction procedures. Frozen tissues (gastrointestinal and carcinoid) were cut separately into small pieces, divided into six portions, and extracted using the following methods: boiling water extraction (10 mL/g tissue), followed by reextraction of the pellet with either (a) 0.5 mol/L acetic acid, pH 1. In all of the CgA assays, the highest peptide concentrations were measured in the boiling water and Tris buffer extracts. Reextraction with acetic acid added up to 15% of the total immunoreactivity, whereas Ͻ5% was obtained after reextraction with carbonate buffer. Acid ethanol extracted Ͻ50% of the immunoreactivity obtained using boiling water.
enzymatic treatment of tissue extracts
For trypsin cleavage, extracts of human gastric antral mucosa, pancreas, carcinoid tumors, pheochromocytoma, and chromatographic fractions (carcinoid) were incubated with equal volumes of 0.2 g/L trypsin in 0.1 mol/L sodium phosphate buffer, pH 7.5, at room temperature for Enzyme-treated extracts were centrifuged at 3000g for 10 min at 4°C. Trypsin-treated antral and pheochromocytoma extracts and controls were assayed with the CgA(13), CgA(1163), CgA(2103), CgA(4301 amide), CgA(3403), and CgA(4439) assays, whereas the extracts of pancreas and carcinoid tumors were analyzed only with the CgA(3403) assay. When the procedure described above was used, the C-terminal dipeptide Arg 438 Gly 439 was cleaved from Tyr-CgA(432-439) and the C-terminal dipeptide Tyr-Cys was cleaved from CgA(1-9)-Tyr-Cys.
plasma samples
Consecutive EDTA plasma samples, drawn over periods of 8 -10 months, were obtained after overnight fasting from three patients with midgut carcinoid tumors. In addition, EDTA plasma samples were obtained after overnight fasting from an additional 10 patients with midgut carcinoid tumors and from 9 patients with pituitary adenomas. To establish reference intervals, plasma samples were also obtained after overnight fasting from 28 healthy control subjects (14 men and 14 women; age range, 27-53 years). The samples were diluted in barbital buffer containing 12.5 mL/L Trasylol ® (20 000 kIU/mL; Bayer) and analyzed at 4°C with the CgA(13), CgA(2103), CgA(4301 amide), and CgA(3403) assays. The use of human plasma was approved by the local ethics committee, and informed consent was obtained from the patients (KF01-352/96 and KF01-290/97).
ria procedure for cga (13) , cga(1163), cga(2103), cga(3403), and cga(4439) assays
Incubation was performed at 4°C using barbital buffer as diluent. The tyrosine-extended CgA fragments were used as calibrators. Tracer solution corresponding to 1000 counts/min was added to calibrator solutions, tissue extracts, chromatographic fractions, and antisera dilutions. After 3 days, the antibody bound and free tracer were separated by the addition of plasma-coated charcoal. The ratio of sample (calibrator, plasma, tissue extract, or chromatography fraction) volume relative to the total final volume varied from 0.06 to 0.18 for the five assays.
Known controls, buffer blanks, and extract blanks (without antiserum added) were included in the assays. The samples were assayed in duplicate. The reliability of the assays was evaluated with respect to detection limit, specificity, and precision. 
Results radioiodination
Of the added 125 I, 67-84% was incorporated in the tyrosine-extended fragments (Fig. 2A) . For all CgA peptides, labeled and nonlabeled peptide separated completely (Fig. 2B) . The nonspecific binding was Ͻ5%. The dilution curves of labeled and unlabeled antigen were parallel for the CgA (13) 125 I-Tyr apparently had a fivefold higher specific activity (5.9 Ci/mol), and because this exceeds the activity of the Na 125 I used, it must be ascribed to a fivefold reduction in affinity of the antibody for the radioactive antigen in spite of the parallel dilution curves for labeled and unlabeled antigen. Thus, the specific activity of this tracer cannot be estimated by selfdisplacement.
evaluation of antibodies
The estimated avidity of the antisera as expressed by the effective equilibrium constant (K eff 0 ) (24, 25 ) varied from 0.1 ϫ 10 12 to 1.0 ϫ 10 12 L/mol ( Table 2 ). The index of heterogeneity, ␣, described by Sips (26 ) , varied between 0.95 and 1.04 for the examined antisera, indicating that the ligand binding is highly homogeneous (27 ) and that each antiserum acts as a solution of monoclonal antibodies (28 ) . The antiserum displaying the highest avidity and titer in each immunization series was selected for additional characterization and used for subsequent measurements. The detection limit was determined in two ways ( Table 3 ). The specificity of the antisera was expressed as the ratio of median inhibitory dose (ID 50 ) for the calibrator peptide vs the ID 50 for the truncated or extended CgA fragments in tracer displacement (Table 4) . Antibody dilution was adjusted to yield a B 0 of 35%. Removal of the two N-terminal amino acids, leucine and proline, of CgA(1-9)-Tyr and the N-terminal leucine of CgA(340 -348)-Tyr substantially decreased the binding with antibodies 94188 and 95060 (Table 4) . Consequently, the N-terminal amino acids constitute an essential part of the epitope for antisera 94188 and 95060, respectively. Correspondingly, removal of Arg 438 Gly 439 minimized the binding with antiserum 95038, corroborating that the dipeptide is an essential part of the epitope for antiserum 95038 (Table 4 The computer homology program FASTA was used to search the SwissProt database for amino acid sequences resembling human CgA(1-9), CgA(116 -124), CgA(340 -348), or CgA(432-439). No relevant sequences other than the corresponding CgA sequences of other mammalian species were found. Dilution curves for tissue extracts (antral mucosa and two carcinoid tumors) were parallel with the calibrator curves for the CgA(13), CgA(1163), CgA(2103), CgA(4301 amide), and CgA(3403) assays (Fig. 3) . In the CgA(4439) assay, none of the three extract dilution curves were parallel with the calibrator curve (Fig. 3) .
specificity of antisera evaluated by tryptic digestion of tissue extracts
Incubation of trypsin with tissue extracts cleaves CgA at numerous basic residues. Hence, trypsin treatment releases the CgA fragment Leu 340 -Lys 355 from further Nand C-terminally extended forms by cleavage after Lys 338 Arg 339 and after Lys 355 , and subsequent quantification by the CgA(3403) assay provides an estimate of the total CgA mRNA translation product, i.e., total CgA. The concentrations measured in the CgA(3403) assay by antibody 95060 were higher after tryptic cleavage than before (Table 5) , and similar results were obtained with antibody 95058. As described above, Leu 340 was shown to constitute an essential part of the epitope for antibody 95060. In combination, these results showed that antibody 95060 is specific for the free NH 2 terminus of CgA(340 -348). The ratio of CgA(3403) immunoreactivity to CgA(3403) immunoreactivity after trypsin provides an estimate of the extent of endogenous cleavage at the basic residues adjacent to the epitope.
Trypsin also cleaves CgA at Lys 9 . The immunoreactivity measured with the CgA(13) assay, using antibody 94188, was not influenced by tryptic cleavage ( Table 6 ), indicating that the antiserum binds CgA(1-9) and larger C-terminally extended molecular forms with equimolar potency. Similar results were obtained with antibody 94185. It is known that trypsin is less effective when acidic amino acid residues are adjacent to the basic residues; consequently, trypsin was not expected to cleave CgA at Arg 115 or Arg 209 . In agreement with this, trypsin had no effect on CgA(1163) or CgA(2103) immunoreactivity (Table 6 After tryptic cleavage of the chromatographic fractions, 25% of the CgA(3403) immunoreactivity eluted as described above. However, the majority of the CgA(3403) immunoreactivity after tryptic cleavage eluted in a broad peak (K d ϭ 0.10 -0.55) that probably includes full-length CgA. The CgA(13), CgA(1163), and CgA(4439) immunoreactivity also eluted with K d values in the range of 0.10 -0.55 (data not shown), suggesting that these assays also detect full-length CgA. The immu- 
quantification of cga in human tissue
In extracts of antral mucosa (Fig. 5) and pancreas, the concentrations measured by the different CgA RIAs varied from 5 to 48 pmol/g and 6 to 121 pmol/g, respectively. In both tissues, the highest concentrations were found using the antisera directed against the NH 2 terminus of sequences adjacent to dibasic cleavage sites, i.e., the CgA(1163), CgA(2103), and CgA(3403) assays. Lower concentrations were measured using antisera specific for the N-terminal epitope of CgA and the pancreastatin antiserum. The CgA(3403) concentration measured after tryptic cleavage (i.e., total CgA) was 63 and 171 pmol/g in the antral mucosa and pancreas, respectively (Table 5) . In carcinoid and pheochromocytoma tumor extracts, the concentrations were approximately 100-to 1000-fold higher (0.50 -34 nmol/g; Figs. 6 and 7). In the six tumors analyzed, the highest concentrations were measured with the antisera specific for the sequences in the mid portion of CgA, and low concentrations were measured with the CgA(13) assay. The CgA(3403) concentration after tryptic cleavage was 5-38 nmol/g.
chromatography of a midgut carcinoid tumor extract
The CgA(3403) immunoreactivity eluted in a narrow peak (K d ϭ 0.69) after that of synthetic CgA(250 -301) amide (K d ϭ 0.62; Fig. 8 ). The CgA(13) assay measured a heterogeneous peak comprising several molecular forms. The CgA(1163), CgA(2103), CgA(4301 amide), and CgA(4439) assays also measured heterogeneous peaks (K d ϭ 0.40 -0.60; results not shown). Fig. 4 . Elution profiles of a carcinoid extract (Table 5 , extract I) after fractionation by Superose HR 12.
The elution position of synthetic hCgA(250 -301) amide is indicated (2) . The chromatography fractions were analyzed with the CgA(3403) assay before (Ϫ Ϫ Ϫ Ϫ) and after (----) treatment with trypsin. In plasma from the carcinoid tumor patients, the CgA(2103) and CgA(3403) assays consistently measured increased concentrations, whereas the concentrations measured with the CgA(13) and CgA(4301 amide) assays were within the reference interval or increased in only some of the samples (Tables 7 and 8 ). In the plasma from nine patients with pituitary adenomas (four growth hormone-producing and five silent), increased concentrations were measured by the CgA(3403) assay, whereas the concentrations measured with the other CgA assays were within the reference interval or increased in only a few samples (Table 9) .
Discussion
The present study describes the development and evaluation of a library of five sequence-specific RIAs for human CgA. The sequences chosen for immunizations are distributed along the entire CgA sequence, adjacent to proteolytic cleavage sites. The antisera raised were of high avidity and homogeneity; when the antisera were used in combination with well-defined monoiodinated tracers, highly sensitive and specific assays were obtained.
Tyrosine-extended CgA peptides were used to radioiodinate the peptides using the chloramine-T method. The CgA(13) assay was found to bind the CgA(1-9) fragment and the extended CgA(1-9)-Tyr-Cys fragment with equimolar potency. Hence, the tyrosyl extension did not affect immunoreactivity. This specific observation implies that the fivefold lower affinity of antiserum 94188 toward CgA (1) (2) (3) (4) (5) (6) (7) (8) (9) 125 I-Tyr compared with CgA(1-9) must be attributed to the presence of iodine atoms on the tyrosine residues. Furthermore, it agrees with the study of Schechter (29 ) , who showed that the combining sites on antibodies bind peptide epitopes corresponding to 4 -6 amino acid residues.
The use of an immunoassay for exact quantitative measurements is based on the assumption of identical binding affinities of antibody toward calibrator and native antigen. If there are major differences in binding affinities, the concentration estimates will be erratic. Parallelism of dilution curves for native antigen and calibrator indicates, but does not prove, identity of binding affinities. Nonparallelism, however, demonstrates major differences and thus precludes quantitative measurements. Dilution curves of tissue extracts revealed nonidentity in the CgA(4439) assay; consequently, this assay can give only semiquantitative estimates. For the other assays, the dilution curves appeared to be parallel. However, because even slight non-parallelism may conceal differences in affinity constants and, hence, errors in estimates of the concentrations of the unknown antigens, the numerical results must be interpreted with caution.
Our results show that the CgA(2103)-and CgA(3403)-specific antisera require a free NH 2 terminus of the CgA(210 -222) and CgA(340 -348) sequences, respectively, for binding. The concentrations measured with these assays in tissue extracts therefore depend on the extent of endogenous cleavage at the dibasic amino acids adjacent to the epitopes. When the CgA(3403) assay is used after trypsin treatment of the extract, an estimate of total CgA immunoreactivity can be made. Whether the CgA(1163) assay is dependent of the free NH 2 terminus is not known, but the chromatography results suggest that the assay detects full-length CgA.
In the extracts of antral mucosa and pancreatic tissue, concentrations between 35-43% and 26 -51%, respectively, of the total CgA immunoreactivity [CgA(3403) after trypsin treatment] were measured with the antisera specific for the NH 2 terminus of the CgA(210 -222) and CgA(340 -348) sequences, whereas only 8% of total CgA immunoreactivity was measured with the CgA(13) assay. Furthermore, the dipeptide Leu 1 Pro 2 was found to be an essential part of the epitope for the CgA(13) assay. Therefore, the low concentrations measured with the CgA(13) assay probably can be attributed to intracellular degradation of CgA, or perhaps to differentiated secretory pathways for CgA-derived peptides. When interpreting the measured pattern of immunoreactive CgA, one must recognize that the CgA(13) and CgA(2103) assays quantify small tryptic peptides and larger peptides with equimolar potency and that the dilution curves of tissue extracts were parallel with the calibrator curves (except for the CgA(4439) assay). However, the influence of molecular differences in the diluted antigens on the concentrations measured with the various CgA assays cannot be excluded.
The chosen extraction procedures (boiling water extraction followed by reextraction with acetic acid) have been used frequently for the extraction of CgA fragments. Accordingly, we found that boiling water (and cold Tris buffer) extraction gave the highest yield, which again is consistent with the hydrophilic nature of CgA, which enables it to remain soluble after boiling (30 ) .
This study is the first to report concentrations mea- Some studies have also used radioimmunochemical quantification of CgA in tumor tissue or in plasma as a marker for neuroendocrine tumors (9 -12, 17-19, 35, 39 -44 ) . In our study, six neuroendocrine tumors expressed 10-fold higher pancreastatin concentrations than those reported previously (31, 39 ) . The CgA concentrations measured in carcinoid tumors with the CgA(315-321) and CgA(332-337) antisera (35 ) were in agreement with our results.
That tumor processing of prohormones varies consid- (31, 35, 39 ) . Cell-specific processing of CgA also has been demonstrated in human cell lines derived from lung cancers and medullary thyroid carcinomas using well-characterized sequence-specific RIAs, chromatography, and Western blot analysis (38, 46 ) . Consistent with the pattern of CgA immunoreactivity in the carcinoid tumors, the CgA concentrations in plasma from carcinoid tumor patients, as measured with the CgA(13) and the CgA(4301 amide) assays, were within the reference interval or increased in only some of the samples. In contrast, when the CgA(2103) and CgA(3403) assays were used, consistently increased concentrations were measured. Increased plasma concentrations of pancreastatin have been described previously in metastatic carcinoid tumors patients (39, 44 ) . The CgA concentrations in plasma from the pituitary adenoma patients were above the upper reference limit when measured with the CgA(3403) assay. Accordingly, increased CgA concentrations have also been described in plasma from a fraction of patients with pituitary adenomas (16, 18, 19 ) .
Our results show that epitope specificity of CgA antisera may profoundly influence diagnostic sensitivity and hence, their usefulness. Furthermore, because tumor processing of proteins may vary considerably, the use of a library of sequence-specific CgA immunoassays, as presented in this study, should improve diagnosis and therapeutic control of neuroendocrine tumors.
